The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Comprehensive Map of FDA-Approved Pharmaceutical Products
Open accessAbstract
With the increasing research and development (R&D) difficulty of new molecular entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention. This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the technical barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems. According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technology barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly technical barriers had less competition and greater market potential. Our study provides a comprehensive insight into FDA-approved products and deep analysis of the technical barriers for advanced drug delivery systems. In the future, the R&D of new molecular entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
WITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
RetractedDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Malam, Y., Loizidou, M., & Seifalian, A. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.004 · Cited by 1,318
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Biodegradable microspheres for protein delivery
Sinha, V. R., & Trehan, A. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00194-9 · Cited by 814
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695
Mechanisms of macromolecule absorption by the lungs
Patton, J. S. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00113-l · Cited by 641
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Clinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462
Zero-order drug delivery: State of the art and future prospects
Laracuente, M.-L., Yu, M. H., & McHugh, K. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.020 · Cited by 384
Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine
Ghitman, J., Biru, E. I., Stan, R., & Iovu, H. (2020) · Materials & Design · doi:10.1016/j.matdes.2020.108805 · Cited by 328
Metadata
- Authors
- Zhong, H., Chan, G., Hu, Y., Hu, H., & Ouyang, D.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2018-12-06
- Volume
- 10
- Issue
- 4
- Pages
- 263
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2902095884
- Cited by
- 288
- References
- 49
- FWCI
- 40.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comprehensive Map of FDA-Approved Pharmaceutical Products. https://app.cochat.ai/papers/10.3390/pharmaceutics10040263
- The paper
- Zhong, H., Chan, G., Hu, Y., Hu, H., & Ouyang, D. (2018). A Comprehensive Map of FDA-Approved Pharmaceutical Products. Pharmaceutics. https://doi.org/10.3390/pharmaceutics10040263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.